References of "HILIGSMANN, M"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPractical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)
de Wit, M.; Cooper, Cyrus ULiege; Tugwell, P. et al

in Aging Clinical and Experimental Research (in press)

There is increasing emphasis on patient-centred research to support the development, approval and reimbursement of health interventions that best meet patients’ needs. However, there is currently little ... [more ▼]

There is increasing emphasis on patient-centred research to support the development, approval and reimbursement of health interventions that best meet patients’ needs. However, there is currently little guidance on how meaningful patient engagement may be achieved. An expert working group, representing a wide range of stakeholders and disciplines, was convened by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the World Health Organization (WHO). Through a structured, collaborative process the group generated practical guidance to facilitate optimal patient engagement in clinical development and regulatory decisions. Patient engagement is a relational process. The principles outlined in this report were based on lessons learned through applied experience and on an extensive dialogue among the expert participants. This practice guidance forms a starting point from which tailoring of the approach to suit different chronic diseases may be undertaken. © 2019, The Author(s). [less ▲]

Detailed reference viewed: 46 (8 ULiège)
Full Text
Peer Reviewed
See detailPatients’ preferences for osteoarthritis treatment: the value of stated-preference studies.
Hiligsmann, M.; Pinto, D.; Dennison, E et al

in Aging Clinical and Experimental Research (2019), 31(1), 1-3

Detailed reference viewed: 31 (7 ULiège)
Full Text
Peer Reviewed
See detailCost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
Hiligsmann, M; Reginster, Jean-Yves ULiege

in Osteoporosis International (2019), 30

Summary. The use of gastro-resistant risedronate, a convenient dosing regimen for oral bisphosphonate therapy, seems a costeffective strategy compared with weekly alendronate, generic risedronate, and no ... [more ▼]

Summary. The use of gastro-resistant risedronate, a convenient dosing regimen for oral bisphosphonate therapy, seems a costeffective strategy compared with weekly alendronate, generic risedronate, and no treatment for the treatment of postmenopausal women with osteoporosis in France. Introduction. Gastro-resistant (GR) risedronate tablets are associated with improved persistence compared to common oral bisphosphonates but are slightly more expensive. This study assessed its cost-effectiveness compared to weekly alendronate and generic risedronate for the treatment of postmenopausal women with osteoporosis in France. Methods. A previously validated Markov microsimulation model was used to estimate the lifetime costs (expressed in €2017) per quality-adjusted life-years (QALY) of GR risedronate compared with weekly alendronate, generic risedronate, and no treatment. Pooled efficacy data for bisphosphonates derived from a previous meta-analysis were used for all treatment options, and persistence data (up to 3 years) were obtained from a large Australian longitudinal study. Evaluation was done for high-risk women 60–80 years of age, with a bone mineral density (BMD) T-score≤ − 2.5 and/or prevalent vertebral fractures. Results. In all of the simulated populations, GR risedronate was cost-effective compared to alendronate, generic risedronate, and no treatment at a threshold of €60,000 perQALY gained. Inwomen with aBMD T-score≤ − 2.5 and prevalent vertebral fractures, the cost per QALY gained of GR risedronate compared to alendronate, generic risedronate, and no treatment falls below €20,000 per QALY gained. In women aged 75 years and older, GR risedronate was even shown to be dominant (more QALYs, less costs) compared to alendronate, generic risedronate, and no treatment. Conclusion. This study provides the first economic results about GR risedronate, suggesting that it represents a cost-effective strategy compared with weekly alendronate and generic risedronate for the treatment of postmenopausal women with osteoporosis in France. [less ▲]

Detailed reference viewed: 21 (3 ULiège)
Full Text
Peer Reviewed
See detailPractical guidance for patient-centred health research.
de Wit, M.; Cooper, C.; Reginster, Jean-Yves ULiege et al

in the lancet (2019), 393

Detailed reference viewed: 38 (4 ULiège)
Full Text
Peer Reviewed
See detailCost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for the prevention of osteoporotic fractures in postmenopausal women at increased risk of fracture.
Hiligsmann, M.; Williams, S.A.; Fitzpatrick, L.A. et al

in Osteoporosis International (2018, April), 29 S1

Detailed reference viewed: 76 (2 ULiège)
Full Text
Peer Reviewed
See detailPatient’s engagement in the identification of critical outcomes in sarcopenia.
Beaudart, Charlotte ULiege; Bruyère, Olivier ULiege; Reginster, Jean-Yves ULiege et al

in Osteoporosis International (2018, April), 29 S1

Detailed reference viewed: 24 (2 ULiège)
Full Text
Peer Reviewed
See detailCost-effectiveness of abaloparatide for the treatment of postmenopausal women with osteoporosis.
Hiligsmann, M.; Williams, S.A.; Fitzpatrick, L.A. et al

in Osteoporosis International (2018, April), 29 S1

Detailed reference viewed: 81 (2 ULiège)
Full Text
Peer Reviewed
See detailPromouvoir la consommation de produits laitiers pour prévenir les fractures: un investissement rentable.
Hiligsmann, M.; Fardellone, P.; Reginster, Jean-Yves ULiege

in Revue du Rhumatisme (Edition Francaise) (2018), 85(3), 220-221

Detailed reference viewed: 14 (2 ULiège)
Full Text
Peer Reviewed
See detailThe projected public health and economic impact of vitamin D fortified dairy products for fracture prevention in France
Hiligsmann, M.; Reginster, Jean-Yves ULiege

in Expert Review of Pharmacoeconomics and Outcomes Research (2018), 18

Background: There is a paucity of research that projects the public health and economic impact of healthcare interventions in the future. In this study, we aimed to estimate the public health and economic ... [more ▼]

Background: There is a paucity of research that projects the public health and economic impact of healthcare interventions in the future. In this study, we aimed to estimate the public health and economic impact of vitamin D fortified dairy products for the years 2020, 2030, 2040, 2050 and 2060. Methods: We used a previously validated Markov microsimulation model that was designed to assess the public health and economic impact of dairy products for fracture prevention in the French general population aged over 60 years in the year 2015. Results: The expected benefit (in terms of fractures prevented) of the recommended intake of dairy products compared to the absence of appropriate intake is expected to increase by 63% in 2040 and by 85% in 2060. The cost per quality-adjusted life years gained of the appropriate intake of dairy products is expected to decrease from €58,244 in 2015 to €42,616 in 2060. Conclusion: The potential public health and economic benefits of vitamin D fortified dairy products is expected to substantially increase in the future, especially in the population aged over 80 years. Decision makers should be aware of the current and future potential benefits of dairy products to protect bone fractures. © 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. [less ▲]

Detailed reference viewed: 14 (4 ULiège)
Full Text
Peer Reviewed
See detailPromoting the consumption of dairy products for fracture prevention: A good value for money?
Hiligsmann, M.; Fardellone, P.; Reginster, Jean-Yves ULiege

in Joint Bone Spine (2018), 85

[No abstract available]

Detailed reference viewed: 25 (5 ULiège)
Full Text
Peer Reviewed
See detailPublic health and economic impact of vitamin D-fortified dairy products for fracture prevention in France.
Hiligsmann, M.; Burlet, N.; Fardellone, P. et al

in Osteoporosis International (2017, March), 28 Suppl 1

Detailed reference viewed: 24 (2 ULiège)
Full Text
Peer Reviewed
See detailPublic Health impact and economic evaluation of vitamin D-fortified dairy products for fracture prevention in France.
HILIGSMANN, M.; BURLET, N.; FARDELLONE, P. et al

in Osteoporosis International (2017), 28(3), 833-840

Summary: The recommended intake of vitamin D-fortified dairy products can substantially decrease the burden of osteoporotic fractures and seems an economically beneficial strategy in the general French ... [more ▼]

Summary: The recommended intake of vitamin D-fortified dairy products can substantially decrease the burden of osteoporotic fractures and seems an economically beneficial strategy in the general French population aged over 60 years. Introduction: This study aims to assess the public health and economic impact of vitamin D-fortified dairy products in the general French population aged over 60 years. Methods: We estimated the lifetime health impacts expressed in number of fractures prevented, life years gained, and quality-adjusted life years (QALY) gained of the recommended intake of dairy products in the general French population over 60 years for 1 year (2015). A validated microsimulation model was used to simulate three age cohorts for both women and men (60–69, 70–79, and >80 years). The incremental cost per QALY gained of vitamin D-fortified dairy products compared to the absence of appropriate intake was estimated in different populations, assuming the cost of two dairy products per day in base case. Results: The total lifetime number of fractures decreased by 64,932 for the recommended intake of dairy products in the general population over 60 years, of which 46,472 and 18,460 occurred in women and men, respectively. In particular, 15,087 and 4413 hip fractures could be prevented in women and men. Vitamin D-fortified dairy products also resulted in 32,569 QALYs and 29,169 life years gained. The cost per QALY gained of appropriate dairy intake was estimated at €58,244 and fall below a threshold of €30,000 per QALY gained in women over 70 years and in men over 80 years. Conclusion: Vitamin D-fortified dairy products have the potential to substantially reduce the burden of osteoporotic fractures in France and seem an economically beneficial strategy, especially in the general population aged above 70 years. [less ▲]

Detailed reference viewed: 8 (2 ULiège)
Full Text
Peer Reviewed
See detailInternational Osteoporosis Foundation and European Calcified Tissue Society working group. Recommendations for the screening of the adherence to oral bisphosphonates.
DIEZ-PEREZ, A; NAYLOR, K.E.; ABRAHAMSEN, B et al

in Osteoporosis International (2017), 28(3), 767-774

Summary: Adherence to oral bisphosphonates is low. A screening strategy is proposed based on the response of biochemical markers of bone turnover after 3 months of therapy. If no change is observed, the ... [more ▼]

Summary: Adherence to oral bisphosphonates is low. A screening strategy is proposed based on the response of biochemical markers of bone turnover after 3 months of therapy. If no change is observed, the clinician should reassess the adherence to the treatment and also other potential issues with the drug. Introduction: Low adherence to oral bisphosphonates is a common problem that jeopardizes the efficacy of treatment of osteoporosis. No clear screening strategy for the assessment of compliance is widely accepted in these patients. Methods: The International Osteoporosis Foundation and the European Calcified Tissue Society have convened a working group to propose a screening strategy to detect a lack of adherence to these drugs. The question to answer was whether the bone turnover markers (BTMs) PINP and CTX can be used to identify low adherence in patients with postmenopausal osteoporosis initiating oral bisphosphonates for osteoporosis. The findings of the TRIO study specifically address this question and were used as the basis for testing the hypothesis. Results: Based on the findings of the TRIO study, specifically addressing this question, the working group recommends measuring PINP and CTX at baseline and 3 months after starting therapy to check for a decrease above the least significant change (decrease of more than 38% for PINP and 56% for CTX). Detection rate for the measurement of PINP is 84%, for CTX 87% and, if variation in at least one is considered when measuring both, the level of detection is 94.5%. Conclusions: If a significant decrease is observed, the treatment can continue, but if no decrease occurs, the clinician should reassess to identify problems with the treatment, mainly low adherence. [less ▲]

Detailed reference viewed: 22 (4 ULiège)
Full Text
Peer Reviewed
See detailPatients' preferences for anti-osteoporosis drug treatment: A cross-European discrete choice experiment
Hiligsmann, M.; Dellaert, B. G.; Dirksen, C. D. et al

in Rheumatology (2017), 56(7), 1167-1176

Objectives. To estimate the preferences of osteoporotic patients for medication attributes, and analyse data from seven European countries. Methods. A discrete choice experiment was conducted in Belgium ... [more ▼]

Objectives. To estimate the preferences of osteoporotic patients for medication attributes, and analyse data from seven European countries. Methods. A discrete choice experiment was conducted in Belgium, France, Ireland, the Netherlands, Spain, Switzerland and the UK. Patients were asked to choose repeatedly between two hypothetical unlabelled drug treatments (and an opt-out option) that varied with respect to four attributes: efficacy in reducing the risk of fracture, type of potential common side effects, and mode and frequency of administration. In those countries in which patients contribute to the cost of their treatment directly, a fifth attribute was added: out-of-pocket cost. A mixed logit panel model was used to estimate patients' preferences. Results. In total, 1124 patients completed the experiment, with a sample of between 98 and 257 patients per country. In all countries, patients preferred treatment with higher effectiveness, and 6-monthly subcutaneous injection was always preferred over weekly oral tablets. In five countries, patients also preferred a monthly oral tablet and yearly i.v. injections over weekly oral tablets. In the three countries where the out-of-pocket cost was included as an attribute, lower costs significantly contributed to the treatment preference. Between countries, there were statistically significant differences for 13 out of 42 attribute/level interactions. Conclusion. We found statistically significant differences in patients' preferences for anti-osteoporosis medications between countries, especially for the mode of administration. Our findings emphasized that international treatment recommendations should allow for local adaptation, and that understanding individual preferences is important if we want to improve the quality of clinical care for patients with osteoporosis. © The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. [less ▲]

Detailed reference viewed: 15 (0 ULiège)
Full Text
Peer Reviewed
See detailA scoping review of the public health impact of vitamin D - fortified dairy products for fracture prevention.
Hiligsmann, M; Neuprez, Audrey ULiege; Buckinx, Fanny ULiege et al

in Archives of Osteoporosis (2017), 12

Purpose : Dairy products are rich in nutrients that positively influence bone health and hence fracture risk, and have therefore been recommended and used for fracture prevention. To help decision makers ... [more ▼]

Purpose : Dairy products are rich in nutrients that positively influence bone health and hence fracture risk, and have therefore been recommended and used for fracture prevention. To help decision makers to efficiently allocate scare resources, it is further important to assess the public health and economic impact of any health intervention. In recent years, several studies have been conducted to estimate the public health and/or economic impact of dairy products but no overview is currently available. This article aims therefore to summarize evidence and review articles that estimated the public health and/or economic impact of vitamin D-fortified dairy products for fracture prevention. Methods: A literature review was conducted using PubMed to identify original studies that assessed the public health and/or economic impact of dairy products (or of calcium/vitamin D supplementation) for fracture prevention up to January 15, 2017. Results: Seven articles were identified. Different stratégies were used by the authors to model the economic/public health impact of dairy products. The four studies assessing the public health impact of dairy products revealed a substantial benefit in terms of fracture prevented, life years, disability-adjusted life years and/or quality-adjusted life years gained. Studies assessing the cost-effectiveness revealed that the use of dairy products is generally cost-effective in the general population aged above 70 years, and from the age of 60 years in populations at high risk of fractures. Conclusion: This systematic review suggests that the use of dairy products could substantially reduce the burden of osteoporotic fractures and seem to be an economically beneficial strategy [less ▲]

Detailed reference viewed: 49 (11 ULiège)
Full Text
Peer Reviewed
See detailPotential cost-effectiveness for using patient decision aids to guide osteoporosis treatment
Penton, H; Hiligsmann, M.; Harrison, M. et al

in Osteoporosis International (2016), 27

We use a model to predict whether using a patient decision aid in patients considering bisphosphonate therapy would be a good use of health resources. We found that if the decision aid improved adherence ... [more ▼]

We use a model to predict whether using a patient decision aid in patients considering bisphosphonate therapy would be a good use of health resources. We found that if the decision aid improved adherence, and only marginally increased time physicians needed with their patients, then the decision-aid would be cost-effective. Introduction Oral bisphosphonates have been shown to reduce the risk of osteoporotic fracture. Adherence is crucial but suboptimal. A recent study suggests that a patient decision aid, which facilitates shared decision-making, could be effective in increasing adherence to bisphosphonates. But decision aids come at a cost in terms of additional time spent with physicians. This study considers the emerging evidence on the role of patient decision aids in improving adherence to bisphosphonates and their potential costs to inform future decision-making and research priorities. [less ▲]

Detailed reference viewed: 24 (2 ULiège)
Peer Reviewed
See detailChemo-mechanical interactions in clay: are the Atterberg limits useful?
Schmitz, R.; Hiligsmann, M.; Schroeder, Christian ULiege et al

in Clays in Natural and Engineered Barriers of Radioactive Waste Confinement - Int. Meeting Reims (2002, December)

Detailed reference viewed: 25 (0 ULiège)